JOURNAL OF CELLULAR AND MOLECULAR MEDICINE-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-06-01 胡同串子羊

审稿速度:3.0 | 投稿命中率:95.0
经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。

65 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-07-23 turing

审稿速度:6.0
偏重的研究方向：干细胞;生信
经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.”

55 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-07-25 围产医学荨麻草

偏重的研究方向：免疫
经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！

54 0

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2020-05-15 1de2d7ccm56(暂无匿称)

我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢

95 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2020-08-19 13801380

请问这个期刊最后会需要原始数据么？

62 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-07-12 145cc87am70暂无昵称

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：肿瘤
经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？

40 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-06-26 turing

审稿速度:6.0 | 投稿命中率:50.0
偏重的研究方向：干细胞;成骨分化
经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。

44 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-06-19 gggg11

审稿速度:1.0 | 投稿命中率:50.0
偏重的研究方向：基础医学;心血管
经验分享：这个杂志要求提供原始数据，大家怎么处理的呢

38 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2020-11-04 Aslan1

三审两个月了，要不要催一下？

126 6

展开6条回复

[GetPortalCommentsPageByObjectIdResponse(id=970075, encodeId=0a9d9e0075c4, content=审稿速度:3.0 | 投稿命中率:95.0 经验分享：投过两篇都中了。第一篇一审2个多月，2个审稿人，一个临床问题特别刁钻，可是我不是临床的，就跟伙伴好好商量着回答了一下，另一个是偏实验的，还好。修回之后二审简单，小修一丢丢接收。第二篇不顺利，主要在于成文以后让我的一作拿去找人乱改，用了很久还没有任何好处，然后字数太多，内容太多，自己作死。回来投稿，一审还是两个多月，很多问题，修改回去就比较nice了，很快接收，赶上一作毕业。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKYPpOWCGE1Mib6UG4HaWVsx4yy5YmEm7nkQHXia8UqeENm5SmukCcXhib2PTRKa8n85enPSeTgRdZBQ/132, createdBy=eca21956848, createdName=胡同串子羊, createdTime=Tue Jun 01 14:49:58 CST 2021, time=2021-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002077, encodeId=f7db10020e743, content=审稿速度:6.0 偏重的研究方向：干细胞;生信 经验分享：under review 5个月，然后没审稿意见，估计都没送审，各位投稿要谨慎，不小心5个月就没有了。。。邮件 “ Your manuscript has been withdrawn from consideration for publication in the Journal of Cellular and Molecular Medicine as we have been unable to provide you with a decision and wish to give you the opportunity to submit it elsewhere. I am sorry for the delays in assessing your manuscript. If you would like us to continue assessing your manuscript, please resubmit it as a new submission.” , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Fri Jul 23 19:14:07 CST 2021, time=2021-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1002626, encodeId=12601002626ab, content=偏重的研究方向：免疫 经验分享：希望这本期刊越来越好~ 编辑回复很及时，当时疫情期间着急毕业，给他们发邮件会回复得很及时，很赞！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cb871661152, createdName=围产医学荨麻草, createdTime=Sun Jul 25 23:51:05 CST 2021, time=2021-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=590912, encodeId=475d5909124f, content=我2月份开始投，27号变成underreview ，4月27号收到邮件小修，5月6日修回，当天收到邮件，submitted and fully consideration for punlication，然后状态变成awaiting ED recommendation 今天5月15号没有什么变化，有投过的各位兄弟姐妹能否回复一下，这个状态要持续多久呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=95, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=48121679018, createdName=1de2d7ccm56(暂无匿称), createdTime=Fri May 15 00:00:00 CST 2020, time=2020-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=811200, encodeId=d40881120068, content=请问这个期刊最后会需要原始数据么？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=62, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a8482359987, createdName=13801380, createdTime=Wed Aug 19 21:32:51 CST 2020, time=2020-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=998896, encodeId=05669988962d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：肿瘤 经验分享：请问各位老师 “Manuscripts Accepted for First Look” 后多久会通知交版面费？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b17b5089126, createdName=145cc87am70暂无昵称, createdTime=Mon Jul 12 21:31:22 CST 2021, time=2021-07-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=977082, encodeId=a3379e70822d, content=审稿速度:6.0 | 投稿命中率:50.0 偏重的研究方向：干细胞;成骨分化 经验分享：3月34日投稿，现在还在审稿，看了大家讨论，基本上是3个月到6个月不等的一审时间，太久了。。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bde21652712, createdName=turing, createdTime=Sat Jun 26 16:12:05 CST 2021, time=2021-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=974932, encodeId=c5ef9e493228, content=审稿速度:1.0 | 投稿命中率:50.0 偏重的研究方向：基础医学;心血管 经验分享：这个杂志要求提供原始数据，大家怎么处理的呢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=28445529202, createdName=gggg11, createdTime=Sat Jun 19 18:52:16 CST 2021, time=2021-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=896944, encodeId=2d8d89694471, content=三审两个月了，要不要催一下？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=acbe2092313, createdName=Aslan1, createdTime=Wed Nov 04 21:11:33 CST 2020, time=2020-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923065, encodeId=b5429230652b, content=Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=98, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=7daa1592248, createdName=liufeng0113, createdTime=Fri Feb 05 18:13:32 CST 2021, time=2021-02-05, status=1, ipAttribution=)]

2021-02-05 liufeng0113

Awaiting EIC Decision快1个月了，不知道这个状态要多久？焦虑中

98 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务